MA47408A - Traitement du cancer - Google Patents

Traitement du cancer

Info

Publication number
MA47408A
MA47408A MA047408A MA47408A MA47408A MA 47408 A MA47408 A MA 47408A MA 047408 A MA047408 A MA 047408A MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A
Authority
MA
Morocco
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
MA047408A
Other languages
English (en)
Other versions
MA47408B1 (fr
Inventor
Anjali Narayan Avadhani
Porre Peter Marie Z De
Yohann Loriot
Ruixo Juan Jose Perez
Arlene O Siefker-Radtke
Kim Stuyckens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/fr
Publication of MA47408B1 publication Critical patent/MA47408B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA47408A 2017-12-20 2018-02-02 Traitement du cancer MA47408B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (fr) 2017-02-06 2018-02-02 Traitement du cancer

Publications (2)

Publication Number Publication Date
MA47408A true MA47408A (fr) 2019-12-11
MA47408B1 MA47408B1 (fr) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (fr) 2017-12-20 2018-02-02 Traitement du cancer

Country Status (5)

Country Link
EA (1) EA201991818A1 (fr)
MA (1) MA47408B1 (fr)
PT (1) PT3576740T (fr)
TW (1) TWI798199B (fr)
WO (1) WO2018141921A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020058432A1 (fr) * 2018-09-21 2020-03-26 Janssen Pharmaceutica Nv Traitement du cholangiocarcinome
EP3898626A1 (fr) 2018-12-19 2021-10-27 Array Biopharma, Inc. Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
EP3923942A1 (fr) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Traitement contre le cancer
US20220202703A1 (en) * 2019-03-15 2022-06-30 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
PH12021552342A1 (en) * 2019-03-29 2022-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MA55486A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
AU2020282816A1 (en) * 2019-05-31 2022-01-06 Qed Therapeutics, Inc. Methods of treating urinary system cancers
CA3176713A1 (fr) 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Utilisation d'inhibiteurs de fgfr pour le traitement de sujets presentant un retard de croissance idiopathique
CN115103678A (zh) * 2020-02-12 2022-09-23 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂
TWI900527B (zh) * 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
WO2022061075A1 (fr) * 2020-09-17 2022-03-24 Ayala Pharmaceuticals Inc. Compositions comprenant des composés de bisfluoroalkyl-1,4-benzodiazépinone pour traiter un carcinome adénoïde kystique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物

Also Published As

Publication number Publication date
WO2018141921A1 (fr) 2018-08-09
PT3576740T (pt) 2023-08-18
TWI798199B (zh) 2023-04-11
EA201991818A1 (ru) 2020-02-05
MA47408B1 (fr) 2023-08-31
TW201839399A (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
EP3488001A4 (fr) Traitement du cancer
IL255261A0 (en) Methods for treating cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA47408A (fr) Traitement du cancer
EP3388004A4 (fr) Instrument de traitement
PL3283527T3 (pl) Leczenie skojarzone nowotworów
EP3448263A4 (fr) Traitement électrothérapeutique
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3432888A4 (fr) Traitement du cancer avec tg02
PL3197456T3 (pl) Leczenie nowotworów
EP3606531A4 (fr) Méthodes de traitement du cancer
MA45429A (fr) Polythérapie pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3610026A4 (fr) Méthodes de traitement du cancer de la vessie
PT3622953T (pt) Tratamento combinado do cancro
MA52627A (fr) Traitement du cancer
EP3546020C0 (fr) Appareil de traitement du cancer
EP3375108A4 (fr) Traitement dewlan
MA46361A (fr) Traitement du cancer de la prostate
EP3733175A4 (fr) Traitement du cancer
DK3576740T3 (da) Cancerbehandling
EP3576791A4 (fr) Traitement du cancer à médiation par calréticuline